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Background: The members of MRE11/RAD50/NBN (MRN) protein complex participates in DNA double-strand break
repair and DNA-damage checkpoint activation. We have previously shown that the p.I171V NBN gene mutation
may contribute to the development of laryngeal cancer. This study tested the hypothesis that variants of the MRE11
and RAD50 genes, previously described as cancer risk factors, predispose to increased susceptibility to head and
neck cancer.
Findings: In this study we analyzed the RAD50 and MRE11 genes in 358 patients: 175 with a single laryngeal cancer
(LC), 115 with multiple primary tumors but one malignancy (primary or second) localized in the larynx (MPT-LC),
68 patients with multiple primary tumors localized in the head or neck (MPT) and 506 controls. No carriers of
previously reported mutation in the MRE11 or RAD50 gene (particularly the pathogenic c.687delT) were detected in
the present study. We identified the p.V127I variant (2/175 LC, 2/506 controls; OR=2.91; 95% CI 0.41-20.85) and p.
V315L variant (2/115 MPT-LC, 1/506 controls; OR=8.96; 95% CI 0.81-99.68) of the RAD50 gene.
Conclusions: Our data indicated that previously described common genetic variations in the MRE11 and RAD50
genes do not contribute to an increased risk of laryngeal cancer and second primary tumors localized in the head
and neck. Prospective studies with larger groups of patients may reveal the possible impact of these genes in
tumor occurrence.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer worldwide and represent
approximately 3% of all malignancies [1]. Despite im-
provements in the diagnosis and treatment of HNSCC,
survival rates of patients with these tumors still remain
at low levels (40-50%), mainly because of the occurrence
of second primary tumors (SPT) [2]. In the etiology of
head and neck cancers and SPT smoking and alcohol
abuse (“condemned mucosa theory”) are essential but
not the only causal factors. Vast majority of patients are* Correspondence: iwziol@man.poznan.pl
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distribution, and reproduction in any mediumcurrent/former smoker and are exposed to many mutagenic
agents which can induce DNA double-strand breaks
(DSB). The MRN complex is involved in DSB repair by
homologous recombination or non-homologous end
joining (NHEJ), telomere maintenance, meiotic recom-
bination, and DNA damage response [3]. Heterozygous
mutations carriers in genes of the MRN complex seem to
be predisposed to cancer development, especially hetero-
zygous NBN mutation carriers have an elevated risk of
acute lymphoblastic leukemia [4], melanoma, colon
and rectum cancer, prostate and breast cancer [5]. The
c.687delT RAD50 mutation was reported with signifi-
cantly elevated frequency in breast cancer patients
from Finland [5-7]. Molecular variants of the MRE11
gene have been identified in breast and ovarian cancer
[5,6,8]. We have previously shown that the heterozygousioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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laryngeal cancer (OR=11.7, 95% CI 1.3–105.2) and multiple
primary tumors (OR=28.35, 95% CI 3.27–245.7) [9]. Like-
wise, in our next studies we found that specific haplotypes
of the NBN gene may be associated with the same cancer
patients [10]. These data prompted us to evaluate the
possible role of the two rest subunits of the MRN protein
complex, the MRE11 and RAD50 genes, in head and neck
cancer susceptibility, especially there are no reports related
to this topic.
Patients and controls
Blood samples were collected from 358 Polish patients:
175 with a single laryngeal cancer (LC) and 115 with
multiple primary tumors but one malignancy (primary
or second primary) localized in the larynx (MPT-LC)
and 68 multiple primary tumors localized in the head
or neck (MPT). The particular characteristics of MPT-
LC/MPT patients were described in our previous studies
[9,10]. None of 175 LC patients with a single laryngeal
cancer developed any second primary tumor during 5
years of observation. All patients included in the MPT-
LC/MPT group fulfilled all the criteria proposed by
Warren and Gates [2] and accepted by the International
Agency for Research on Cancer (IARC). In all 115
MPT-LC patients, either the index or the second tumor
was laryngeal cancer. In total, 506 anonymous blood
samples collected on Guthrie cards, matched regionally
to cancer patients were used as population controls. All
patients signed informed consent forms approved by the
Ethics Committee of the University of Medical Sciences
in Poznań.
Methods
The PCR-MSSCP method was used to analyze the coding
sequence and exon-intron boundaries of exon 3, 4, 5,
7, 21 and 25 of the RAD50 gene as described in our
previous study [11] and exon 5, 8, 9, 10, 14, 15, 17 and
19 of the MRE11 gene. The selection of the screened
regions was based on the reported occurrence of the
mutations in cancer in former studies. All samples were
analyzed by multitemperature single-strand conform-
ation polymorphism (MSSCP) method (Biovectis, Warsaw,
Poland). Samples that showed an aberrant shift in MSSCP
were sequenced (OLIGO, IBB, Warszawa). The signifi-
cance of differences between studied groups was assessed
by the χ2 test or Fischer’s exact test, depending on vari-
ants’ frequency (GraphPad Software Inc. San Diego,
CA). Crude odds ratios (ORs) were calculated and given
with 95% confidence intervals (CIs). The differences were
considered significant if the value of probability (P) less
than 0.05. To account for false-positive findings, multiple
testing correction was carried out by Bonferroni correc-
tion [P-value * n (number of genes in test) <0.05] [12].Because we tested 2 genes, the gene will be significant if
the corrected P-value is below the cutoff of <0.025.
Results
The RAD50 c.687delT was not observed among 358
cancer patients and 506 controls. We have identified 3
heterozygous sequence variants (Table 1). Two of them
were missense variants (p.V127I and p.V315L). These two
missense variants were evaluated for possible functional
effect on RAD50 protein by SIFT and PolyPhen analysis
[11] which suggested that both variants are predicted
to be tolerated. The c.3876C>T variant was synonym-
ous (p.N1292N). No significant differences in variants
frequencies were observed when comparing 2 groups
of cancer patients with controls (Table 1). In intron 4
we have identified one polymorphism c.551+19G>A
(rs17166050) (Table 2), in which heterozygous geno-
type GA was significantly more frequent, even after
multiple testing correction, in controls than in MPT
group (P=0.0205). We did not find any sequence variants
in the MRE11 gene, beside intronic c.1783-86delAG
(Table 1).
Discussion
In the current preliminary study we screened the selected
regions, where most of already known molecular variants
of the RAD50 and MRE11 gene occur, among 358 head
and neck cancer patients and 506 controls. To our
knowledge the first prospective investigation of its kind,
we have shown that MRE11 and RAD50 genes do not
contribute to laryngeal cancer. The c.687delT RAD50
mutation, not identified in our study, was reported with
significantly elevated frequency in breast cancer patients
from Finland [5-7]. This pathogenic mutation generates
a truncated protein without the important C-terminal site
and it is a founder mutation in Finland, which increases
4-fold risk of breast cancer in Finnish women [7]. How-
ever, the occurrence of the c.687delT mutation in other
populations has been difficult to confirm among non-
BRCA1/2 hereditary breast cancer patients from the UK
[13] and France [14]. Similarly the deletion was not
detected in our previous study among Polish non-selected
breast cancer patients [11], which is in agreement with
results of the current study. It seems that pathogenic
variants of the RAD50 gene may have a impact to cancer
development only in certain populations, like Finnish.
The potential role of the MRE11 gene in human can-
cers is not well documented. Only J. Bartkova et al. have
identified two germline mutations: a missense mutation
p.R202G and a truncating mutation p.R633X, which
qualify the MRE11 as a candidate breast cancer suscep-
tibility gene in a subset of non-BRCA1/2 families in
Denmark [8]. We did not find any mutations in our
group of subjects which confirm that genetic variants of
Table 1 The RAD50 and MRE11 gene variants detected in laryngeal cancer (LC), multiple primary tumors with laryngeal





LC MPT-LC MPT Controls
n = 175 n = 115 n = 68 n = 506
OR (95% CI) OR (95% CI) OR (95% CI)
RAD50 Ex. 4 c.379G>A p.V127I 2 - - 2
2.91 (0.41-20.85)
Ex. 7 c.943G>T p.V315L - 2 - 1
8.96 (0.81-99.68)
Ex. 25 c.3876C>T - 1 - - 0/180
8.71 (0.35-215)
MRE11 Int. 16 c.1783-86delAG - 39 18 20 61/279
1.03 (0.65-1.62) 0.66 (0.37-1.18) 1.49 (0.82-2.69)
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rare. However aberrant expression has been commonly
observed and it is supposed that MRE11 overexpression
may be the mechanism increasing risk of malignancy
development.
Beside mutations and pathogenic variants of the
MRN genes, sets of single nucleotide polymorphisms
(SNP) were tested for association with many cancers
such non-Hodgkin lymphoma (NHL) [15], breast can-
cer [16] and bladder cancer [17]. J. Schuetz et al. find
that two variants in RAD50 were suggestive of associ-
ation with specific non-Hodgkin lymphoma (NHL)
European cases, but there were not significant after
correction of multiple tests. In the same study, the
rs17166050 polymorphism was detected in intron 4 of
the RAD50 gene and showed no association with NHL
[15]. Similar results were reported in our current and
previous study among non-selected breast cancer patients
[11]. In our another study we confirmed the associ-
ation of the variant allele of the RAD50 rs171660505
with decreased risk of the childhood acute lympho-
blastic leukemia [18]. A. Choudhury and colleaguesTable 2 The RAD50_rs17166050 genotypes/allele frequency d
ratio and 95% confidence interval) in laryngeal cancer (LC), m
multiple primary tumors of head and neck (MPT) and control
Genotype/allele Controls LC OR (95% CI)
n (%) n (%)
GG 233 (47) 87 (50) 1*
GA 195 (40) 69 (39) 1.06 (0.74-1.53)
AA 66 (13) 19 (11) 1.30 (0.74-2.29)
GA+AA 261 (52) 88 (50) 1.11 (0.78-1.56)
G 661 (66) 243 (69) 1*
A 327 (34) 107 (31) 1.12 (0.87-1.46)
*Reference category; OR (95% CI) – odds ratio (95% confidence interval); † Result stahave genotyped SNPs in DSB signalling genes and
found an marginally association of the MRE11 3′UTR
SNP rs2155209 with bladder cancer [17]. In another
study, H. Hsu et. al has excluded any association of the
RAD50/MRE11 polymorphisms and breast cancer risk,
beside one SNP in NBN [16]. However, an increased risk
of developing breast cancer was found in women harbor-
ing a greater number of putative high-risk genotypes of all
MRN genes. It seems that genes which are not associated
with cancer independently, could modify cancer risk
jointly or in combination with other variants.
In conclusion, current results demonstrate that RAD50/
MRE11 variants occur at very low frequency in analyzed
group of cancer patients in Poland. It seems that only
the p.I171V NBN gene may be associated with head
and neck cancer. However, the lack of evidence of the
common RAD50/MRE11 gene variants in this prelim-
inary study, should be verified in replication studies.
Depending on genetic heterogeneity of head and neck
tumors and population diversity, prospective studies
with larger groups of patients may reveal the possible
impact of the MRN complex genes in tumor occurrence.istribution and logistic regression analysis (with odds
ultiple primary tumors with laryngeal cancer (MPT-LC),
s
MPT-LC OR (95% CI) MPT OR (95% CI)
n (%) n (%)
50 (44) 1* 24 (35) 1*
57 (50) 0.73 (0.48-1.12) 38 (56) 0.53 (0.31-0.92)†
8 (6) 1.78 (0.80-3.92) 6 (9) 1.13 (0.44-2.89)
65 (57) 0.86 (0.57-1.30) 44 (65) 0.61 (0.36-1.04)
157 (68) 1* 86 (63) 1* 0.85
73 (22) 1.06 (0.78-1.45) 50 (37) (0.59-1.24)
tistically significant (p=0.0205).
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